--- title: "MacroGenics Sells Maryland Biologics Manufacturing to Bora" type: "News" locale: "en" url: "https://longbridge.com/en/news/286105216.md" description: "MacroGenics has agreed to sell its Maryland biologics manufacturing operations to Bora Pharmaceuticals for $122.5 million, with an additional $5 million tied to future milestones. The deal, expected to close in Q3 2026, will transfer around 140 employees and an FDA-approved facility to Bora. MacroGenics will retain its research operations and gain non-dilutive capital to support its oncology pipeline. Analysts rate MGNX stock as a Buy with a $6.00 price target, though concerns about financial performance persist." datetime: "2026-05-12T12:56:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286105216.md) - [en](https://longbridge.com/en/news/286105216.md) - [zh-HK](https://longbridge.com/zh-HK/news/286105216.md) --- # MacroGenics Sells Maryland Biologics Manufacturing to Bora ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks MacroGenics ( (MGNX) ) just unveiled an update. On May 11, 2026, MacroGenics agreed to sell its GMP drug substance manufacturing operations, including its CDMO business, Maryland manufacturing site and warehouse, and associated liabilities and personnel, to Taiwan-based Bora Pharmaceuticals for $122.5 million in cash at closing, plus up to $5 million tied to future manufacturing milestones. The transaction, expected to close in the third quarter of 2026 subject to customary conditions, will shift roughly 140 MacroGenics employees and its FDA-approved 11,000-liter facility to Bora, while MacroGenics retains research operations, secures ongoing manufacturing and supply access via new agreements, and gains non-dilutive capital to further its oncology pipeline, as Bora expands its North American biologics CDMO footprint. The most recent analyst rating on (MGNX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page. **Spark’s Take on MGNX Stock** According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral. The score is weighed down primarily by weak financial performance—ongoing losses and significant cash burn with worsening free cash flow—despite moderate leverage. Technicals are mixed but not broken, and corporate events provide some funding relief and a positive regulatory update, tempered by material safety/hold-related uncertainty. To see Spark’s full report on MGNX stock, click here. **More about MacroGenics** MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company leverages proprietary next-generation antibody platforms and protein engineering expertise to generate its pipeline and maintains strategic collaborations with global pharmaceutical and biotechnology partners. **Average Trading Volume:** 1,028,356 **Technical Sentiment Signal:** Buy **Current Market Cap:** $190.7M Find detailed analytics on MGNX stock on TipRanks’ Stock Analysis page. ### Related Stocks - [MGNX.US](https://longbridge.com/en/quote/MGNX.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)](https://longbridge.com/en/news/286391219.md) - [MacroGenics Q1 revenue rises, beats estimates on client production and cancer drug royalties](https://longbridge.com/en/news/286310410.md) - [](https://longbridge.com/en/news/286807703.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Incyte expands Genesis Molecular AI collaboration, pays USD 120 million upfront](https://longbridge.com/en/news/287060301.md)